Last reviewed · How we verify
amosartan and rosuvastatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
amosartan and rosuvastatin (amosartan and rosuvastatin) — Hanmi Pharmaceutical Company Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| amosartan and rosuvastatin TARGET | amosartan and rosuvastatin | Hanmi Pharmaceutical Company Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- amosartan and rosuvastatin CI watch — RSS
- amosartan and rosuvastatin CI watch — Atom
- amosartan and rosuvastatin CI watch — JSON
- amosartan and rosuvastatin alone — RSS
Cite this brief
Drug Landscape (2026). amosartan and rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/amosartan-and-rosuvastatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab